MicroRNAs play a major role in cancer development and also act as a key factor in many other diseases. In this investigation, we propose three methods for handling miRNA expressions. The first two methods determine whether a miRNA is indicating normal or cancer condition, and the third one determines how many miRNAs are supporting the cancer sample/patient. While, Method 1 acts as two class classifier and based on normalized average expression value, Method 2 also does the same and based on the normalized average intraclass distance. Method 3 checks whether a miRNA belongs to the cancer class or not, provides the percentage of supporting miRNAs for a cancer patient, and is based on weighted normalized average intraclass distance. The values of the weights are determined using exhaustive search by maximizing the accuracy in training samples. The proposed methods are tested on the differentially regulated miRNAs in three types of cancers (viz., breast, colon and melanoma cancer). The performances of Method 1 and Method 2 are evaluated by F score, Matthews Correlation Coefficient (MCC) and plotting '1 − Specificity vs. Sensitivity' in Receiver Operating Characteristic (ROC) space and are found to be superior to the kNN and SVM classifiers for breast, colon and melanoma cancer data sets. It is also observed that both, the sensitivity and the specificity, of Method 1 and Method 2 are higher than 0.5. For the same data sets, Method 3 achieved an average accuracy of more than 98% in detecting the miRNAs, supporting the cancer condition.
I. INTRODUCTION
MicroRNAs (miRNA) are a special type of non coding RNAs [13] , [17] , which are found in every living organism having eukaryotic cell and directly work with messenger RNAs (mRNA) [2] , [6] , [9] , [19] . Non coding RNAs are those RNAs, which are not directly associated with protein coding functions. MiRNAs indirectly take part in various biological and pathological processes by inhibiting the translation process (the process of generation of protein from mRNA) of mRNA. In this inhibiting process, mature miRNA creates bond with RNA Induced Silencing Complex (RISC) and produce miRISC [20] . This miRISC binds its 5' Untranslated Region (5' UTR), to the 3' Untranslated Region (3' UTR) of the targeted mRNA by Watson-Crick base pairing mechanism [20] and the translation process does not proceed further [3] , [8] , [15] .
Deregulation of miRNA expression is one of the major causes of the development of cancers in animal body [10] . It causes the cells of a tissue to fail to exit from cell cycle in proper time [18] and the cells go for uncontrolled divisions and suppress the activities of the other cells. As a consequence, animal body becomes very sick and unable to survive without any treatment. MiRNAs are also considered as major biomarkers of various other human diseases, like viral infection, metabolic disorders etc. Now, given a sample (patient) with expression values of miRNAs, the task can be the classification of each miRNAs as either normal or cancer. In this regard, we propose two methods (Method 1 and Method 2) by viewing the problem as two class classification problem, where, the task is to check how many miRNAs are indicating the normal and the cancer conditions of a given patient. On the other hand, the problem can be also be viewed as, identifying miRNAs supporting the cancerous condition of a given cancer patient. To handle this problem we propose Method 3, where the aim is to determine how many miRNAs are supporting the condition of a cancer patient.
The rest of this article is organized as follows. In Section II, some existing approaches are described. The details about the miRNA generation, miRNA expression, data sets and the proposed investigation are described in Section III. In Section IV, experimental results are reported. Finally, Section V concludes this investigation.
II. EXISTING APPROACHES
The first investigation in the field of miRNA and its role on cancers was investigated in 2002 [4] . The application of computational techniques comes in the scenario for their inexpensiveness and time saving benefit [10] .
In [10] , 334 mammalian tissue samples, including both the normal and the cancer samples, are collected and 217 different miRNAs are extracted from the collected tissues. Hierarchical clustering is then performed (using Pearson correlation and average linkage) on the generated miRNA expressions. The method separates the expressions according to the location of their origins. It is also shown that, miRNA expressions are more informative than the mRNA expressions, even in the case of very little sign of cancer.
Investigations are also conducted [3] to extract the normal and the cancer miRNA expressions. It is shown that the normal and the cancer miRNA expressions are making different clusters using average linkage hierarchical clustering with Pearson correlation as similarity measure. It is also observed that, miRNAs express themselves differently for different breast cancer subtypes.
From the investigations in [3] , [10] and [22] , it is observed that, miRNA expression values are determined using biochemical methods and then clustering techniques are applied to differentiate the origin of their tissue locations. Later, emphasis is given on the separation of the normal and the cancer miRNA expressions [3] , [10] , [22] and the separation of the subclasses for a particular type of cancer [3] . In [12] , miRNAs responsible for the melanoma cancer are identified and 16 miRNAs are pointed out, which show significant deregulation in the cancer patients. Reviews on some other existing methodologies are available in [5] , [16] , and [21] .
Most of the existing investigations are mainly focused on determining the nature (i.e., expression values) of the miRNAs in different stages (normal and cancer) and classifying samples by using miRNAs as features. In this article, we deal with the problem of predicting the condition (normal or cancer) of miRNAs (i.e., considering miRNAs as patterns) and also finding the supporting miRNAs for a given cancer patient.
III. MATERIALS AND METHODS
The natural biochemical process, by which generation of miRNA from miRNA genes takes place, involves four steps [5] , [8] , [11] , [20] - [22] . These are as follows: 1) Generation of primary miRNA transcripts: At the first step, primary miRNA transcripts (primiRNA), of length ~1000 nt, are generated from the miRNA genes in the nucleolus.
2) Generation of precursor miRNA: pri-miRNA is then cleaved by RNase endonuclease-III enzyme Drosha and its partner DGCR8/Pasha in the nucleus and generates precursor miRNA (pre-miRNA) of length ~60-100 nt.
3) Transportation of Pre-miRNA into cytoplasm: The generated pre-miRNA is transported from nucleus to cytoplasm through the pores of the nuclear membrane by the proteins RanGTP and exprotin-5. 4) Generation of mature miRNA: Pre-miRNAs are further cleaved by Dicer enzyme and generates ~22 nt mature miRNA duplex, containing a guide stand and a passenger stand. From this duplex, passenger stand degrades and the guide stand generates simplex mature miRNA.
The mature miRNAs can be classified into intergenic and intragenic miRNAs, based on the location of miRNA coding genes. While, in intergenic miRNA, miRNA-coding genes are located in between protein-coding genes, in intragenic miRNA, miRNA-coding genes are located within their host protein-coding genes.
A. MiRNA Expression Generation
There are three major processes, by which miRNA expressions can be obtained [7] . They are as follows:
1) MiRNA expression profiling by cloning and sequencing: This process is accomplished by isolation of mature miRNA, adaptor ligation, reverse transcription and polymerase chain reaction (PCR) amplification. 2) Microarray analysis: The steps to prepare microarray for miRNA expressions involve oligonucleotide probe design, preparation of labeled material from RNA samples (with amplification or without amplification) and microarray preparation. 3) Microbead expression analysis: One of the successful methodologies in this type of technology is xMAP, where, 100 different miRNAs can be analyzed in one reaction. Each miRNA is treated as a microbead and each microbead has its own identity as a color (fluorescent dye) code. The amount of a particular miRNA can be scanned as the intensity value of the color, and this intensity value is stored as the expression of that miRNA.
B. Data Sets
In this investigation we used three different types of cancer data sets, viz., breast [3] , colon [1] and melanoma [12] . While the breast cancer data set consists of 98 (5 normal + 93 cancer) samples and 309 miRNA expressions, the colon cancer data set consists 66 (8 normal + 58 cancer) samples and 287 miRNA expression values and the melanoma cancer data consists of 57 (22 normal + 35 cancer) samples and 866 miRNA expressions. In [3] , out of 309 miRNAs, 38 miRNAs are pointed out as differentially expressed in the normal and the cancerous breast samples. Similarly, in [1] and [12] , 37 out of 287 and 51 out of 866 miRNAs are identified as differentially expressed between the normal and the cancer samples in colon and melanoma, respectively. Hence in our investigation those differentially expressed miRNAs are only considered for further study. Table I summarizes the details of the data sets.
C. Proposed Approaches
As said earlier, the main issues tackled in this investigation are: i) to check how many miRNAs are indicating the normal and the cancer conditions of a given patient, and ii) to check how many miRNAs are supporting a cancer patient's condition.
In this regard we proposed three methods, among which, Method 1 and Method 2 deal with the first issue and Method 3 deals with the second issue. For all of these methods, we used leave-one-out cross validation procedure, where, at a particular instance one sample is kept for testing purpose and all other samples are used for training. The process is then repeated for all the samples one by one. The performance of a method is then judged by the average result over all the samples. Now we will discuss the proposed methods in detail.
1) Method 1: In this method, given a miRNA with the normal and the cancer samples, we calculated the normal representative by taking the ratio of mean and standard deviation of the normal expressions of that miRNA. The cancer representative is also calculated in a similar manner by using the cancerous expressions of the same miRNA. Now for the test sample first we consider one of its expressions corresponding to the given miRNA and two values are generated from that expression by normalizing it with standard deviation of the normal and the cancer expressions, respectively. For these two values, city block distances are then calculated from the normal and the cancer representatives, respectively, and the decision for the miRNA expression, chosen from the test sample, is taken according to the closeness of those values to the representative of each class (normal or cancer). To find how many miRNAs of a test sample are normal and how many are cancerous, we repeat the process for all the miRNAs. The steps for Method 1 are given below: S1) In the training phase, calculate the representative of the kth miRNA in the normal and the cancer classes, if test sample is chosen from the set of the normal samples, as
, ∉Tn
respectively. If the test sample is chosen from the cancer samples, then, calculate the representative of the kth miRNA in the normal and the cancer classes as
respectively, where, and represent standard deviations of the normal and the cancer expression values, respectively, of the kth miRNA.
S2) In the testing phase, the goal is to find whether an unknown miRNA expression for the test sample is normal or cancer. In this regard, S2a) Normalize the kth miRNA expression of the test sample with and and represent them as = (5) and = , (6) respectively, where, is the expression value of the kth miRNA of the test sample. S2b) Select the kth miRNA of the test sample as the normal one if it satisfies the condition:
and select the kth miRNA as cancerous if it satisfies the condition
S3) Repeat steps, S1 to S2 for all k (i.e., for all the miRNAs in the test sample), where, k=1, 2, ...., L.
S4) Repeat steps S1 to S3, for all the samples considering as test sample one by one.
S5) Evaluate the performance of the method in terms of F score, Mathews Correlation Coefficient (MCC) and by plotting '1 -Specificity vs. Sensitivity' in receiver operating characteristic (ROC) space.
The F score is defined as:
where, the sensitivity (Sn) is defined as
where, the specificity (Sc) is defined as
The MCC is defined as
Here, the true positive refers to the number of correctly detected cancer miRNA expressions and false negative refers to the number of undetected cancer miRNA expressions. True negative implies the number of correctly detected normal miRNA expressions and false positive implies the wrongly detected cancer miRNA expressions (i.e., detected as cancer expressions, but actually they are normal expressions). The value of MCC lies between -1 to +1, where, MCC value less than zero implies prediction capability worse than random prediction and greater than zero indicates the prediction capability better than random prediction. In the ROC space, any point on the straight line, passing through the coordinates (0, 0) and (1, 1) (see Fig. 2 (a), Fig. 2(b) and Fig.2(c) ), indicates that the prediction performance is the same as that of random prediction. On the other hand, coordinate (0, 1) implies a perfect prediction and the coordinate (1, 0) indicates a totally wrong prediction.
2) Method 2: In this method, the average intraclass distance for the normal and the cancer class are calculated by using the corresponding class mean and all expression values for that miRNA in that class. Then, the average intraclass distances, for normal and cancer class, of that miRNA are normalized with the standard deviation of the normal and the cancer expressions of that miRNA, respectively. For the same miRNA, the city block distance between the unknown expression (test sample) and the class mean of the normal training samples is calculated and normalized by the standard deviation of the normal training samples of that miRNA. Similarly, for the same miRNA the process is repeated for the unknown expression and the class mean of the cancer training samples. Decision (normal or cancer) for the unknown miRNA in the test sample is then taken according to the closeness of the normalized city block distances with the normalized intraclass distances. The whole process is then repeated for all the miRNAs of a given test sample.
Let, N, M and L are the total number of the normal samples, the cancer samples and miRNAs, respectively, in a data set. The i th (i=1, 2, ...., N) normal expression value of the k th (k=1, 2, ...., L) miRNA is represented as and the j th (j=1, 2, ...., M) cancerous expression of the k th miRNA is represented as . As we are using leave-one-out crossvalidation, the number of training samples in the normal and the cancer samples is N-1 and M, respectively, when the test sample (say Tn) is selected from the normal samples. Similarly, there is N and M-1 numbers of training samples, respectively, if the test sample (say Tc) is selected from the cancer samples.
The steps for Method 2 are as follows: S1) If the test sample is chosen from the normal samples, calculate the normalized average intraclass distance of the k th miRNA in the normal class as
, ∉ (13) where, µ and represent the mean and the standard deviation of the normal expression values of the kth miRNA, respectively. The normalized average intraclass distance of the kth miRNA in the cancer class is calculated as,
where, the mean and the standard deviation of the expression values of the kth miRNA in the cancer class are represented as µ and , respectively. 
and cancerous if
S4) Repeat Steps S1 to S3 for all the values of k (k=1, 2, ..., L) of a given sample. S5) According to the leave-one-out cross-validation procedure, select all samples from the whole set one by one as test sample and repeat Steps S1 to S4. S6) Evaluate the performance of the method by F Score, MCC value and by plotting '1 −Specificity vs. Sensitivity' in ROC space in a similar way to Method 1.
3) Method 3: As mentioned in Section I, here we discuss about Method 3, which can be used to identify the miRNAs, supporting cancerous condition of a given cancer patient. In this regard, in the training phase we only used known cancer samples and in testing phase, we checked whether a miRNA expression is supporting cancerous condition or not. Finally, we determined how many miRNAs are supporting cancerous condition of a sample. Here, we introduced a weight factor which is determined through exhaustive search by maximizing the predicting accuracy, using the training samples. The steps for determining the condition of a miRNA by this method is given below.
Let, M and L are the total number of the cancer samples and miRNAs, respectively, in a data set. Hence, the number of the training samples and the test sample will be M-1 and 1, respectively, according to leave-one-out cross-validation method. The expression value of the j th (j=1, 2, ...., M) cancer sample of the kth (k=1, 2, ...., L) miRNA is represented as .
The steps for Method 3 are as follows: S1) In a way similar to Step S2 in Method 2, in the training process, calculate the normalized average intraclass distance of kth miRNA in the cancer class as 
Repeat steps S5 to S6 for all values of k (i.e., for all miRNAs), where, k varies from 1 to L.
S7) Calculate the percentage of supporting miRNA for the i th sample as = × 100
where, is the number of correctly detected supporting miRNAs for a cancer patient. S8) Select all the samples from the whole set one by one as test sample and repeat
Steps S1 to S8 and calculate the average (say pc) of the obtained results as
where, M is the number of samples.
IV. EXPERIMENTAL RESULTS
The proposed methods are tested on subsets of miRNAs, which are identified as differentially expressed in breast, colon and melanoma cancer, are only considered. First, the performances of Method 1 and Method 2 are compared with the performance of the fold change of miRNAs in normal and cancer cells, k-nearest neighbour (kNN) classifier and SVM classifier, and then the performance of Method 3 is compared with only fold change based method as Method 3 does not handle the problem as a two class classification problem, like kNN and SVM classifiers.
Fold change [14] (say F) of a miRNA is defined as the ratio between its normalized mean expression values of the cancer class (say tc) and its normalized mean expression value of the normal class (say tn). These fold change values indicate whether the fold change is positive or negative for a particular miRNA. For an unknown miRNA, we generated two values (say un and uc) by normalizing its expression with the standard deviation of the normal and the cancer class of that miRNA, respectively. Now for a miRNA with positive fold change (i.e., F > 1), it is considered as cancerous if the ratio of uc and tn is greater than or equal to F (i.e., ≥ ) and it is considered as normal for the opposite condition (i.e., < ). For a miRNA with negative fold change (i.e., 0 < F < 1), we calculated the ratio of uc and tn, and if it is less than or equal to F (i.e., ≤ ), it is considered as cancerous. A miRNA (with negative fold change value) is selected as normal if it satisfies the opposite condition (i.e., > ). Finally, leave-one-out cross-validation procedure is used for evaluating the performance of the method.
The comparison between Method 1 and fold change based method on three different data sets, in terms of F score is presented in Fig. 1(a) . Similarly, Fig. 1(b) represents the comparison between Method 2 and fold change on three different data sets in terms of the same measure. It is observed that the F score values for breast, colon and melanoma cancer data sets are 0.5703, 0.7487 and 0.8324, respectively, for Method 1 and for Method 2, F scores are 0.5669, 0.7506 and 0.8342 for breast, colon and melanoma cancer data sets, respectively. On the other hand, values of F score for breast, colon and melanoma cancer data sets are 0.5038, 0.6090 and 0.5319, respectively, in fold change based method. Hence, it can be said that Method 1 and Method 2 perform better than fold change based method in terms of F score. It is also seen, for different data sets, while the sensitivity varies from 0.6637 to 0.8372 and 0.6643 to 0.8420 for Method 1 and Method 2, respectively, the specificity varies from 0.5100 to 0.8128 and 0.5044 to 0.8155, respectively.
The comparisons of Method 1 and Method 2 with SVM and kNN (where, k=1, 2, 3, 4), in terms of F score, is reported in Table II . It is obtained from the table that, F score varies from 0.5768 to 0.8324 We also tested the performance of Method 1, Method 2, SVM and kNN in receiver operating characteristic (ROC) space. As mentioned earlier we plotted '1 − Specificity vs. Sensitivity' in this space. Here, any point on the straight line, passing through the coordinates (0, 0) and (1, 1) , indicates that the prediction performance is the same as that of random prediction. On the other hand, coordinate (0, 1) implies a perfect prediction and the coordinate (1, 0) indicates a totally wrong prediction. The results in ROC space for the above mentioned methods are shown in Fig. 2(a As mentioned earlier, given a cancer patient, Method 3 provides the number of miRNAs, supporting the cancerous condition of a sample. Note that, in a part of the process Method 3 also identifies those miRNAs. Hence, the performance of Method 3 is compared with the performance of the fold change based technique in terms of the percentage of supporting miRNAs in the cancer sample. In the fold change based method, a miRNA, with positive fold change value, is selected as supporting miRNA for cancer sample if the ratio of uc and tn is greater than or equal to F (i.e., ≥ ) where, uc is the unknown expression normalized with the standard deviation of the cancer class and tn is the average normal expression normalized with the standard deviation of the normal class. A miRNA, with negative fold change value, is considered as supporting miRNA if the ratio of uc and t n is less than or equal to F (i.e., ≤ ). In this article, we proposed two approaches (Method 1 and Method 2) for identifying whether a miRNA is indicating normal or cancer condition, and one approach (Method 3) to check how many miRNAs are supporting the condition of a cancer sample. While, the first method is based on normalized average expression value, the second method deals with the normalized average intraclass distance and the third method is based on weighted average normalized intraclass distance. Experiments are performed on breast, colon and melanoma cancer data and it is observed that sensitivity, specificity and F score for Methods 1 and 2 are above 0.66, 0.50 and 0.56, respectively. Hence, these methods can also be used for condition prediction of an unknown patient. MCC values for Method 1 and Method 2 are found to be positive for all the data sets. It is also observed that the first two methods perform better than kNN and SVM classifiers in terms of average F-score, average MCC and plots in ROC space for all types of data sets. Note that, result of SVM depends on the proper kernel selection and also on the selection of the parameters of the kernel, if applicable, and the result of kNN also depends on the selection of value of 'k'. In the contrary, Method 1 and Method 2 do not have any parameter to set manually and they also consider the expression variation among the samples. Experimental results, on the same three data sets show that the supporting miRNAs predicted by method 3 is above 98% for all the data sets. Although, the SVM and kNN classifiers are not compared with the Method 3, as this method does not handle the issue as a two class problem, experimental results on multiple date sets revealed the potential value of our approach. Table I : Summary of the used data sets. 
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